LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance